Blueprint Medicines Backtesting

Blueprint Medicines Corporation -- USA Stock  

USD 66.83  1.9  2.93%

With this equity back-testing module your can estimate the performance of a buy and hold strategy of Blueprint Medicines Corporation and determine expected loss or profit from investing in Blueprint Medicines over given investment horizon. Check also Blueprint Medicines Hype Analysis, Blueprint Medicines Correlation, Blueprint Medicines Valuation, Blueprint Medicines Volatility as well as analyze Blueprint Medicines Alpha and Beta and Blueprint Medicines Performance
Investment Horizon     30 Days    Login   to change
SymbolX
Backtest

Blueprint Medicines 'What if' Analysis

September 18, 2017
 0.00 
No Change 0.00  0.0%
In 31 days
October 18, 2017
 0.00 
If you would invest  0.00  in Blueprint Medicines on September 18, 2017 and sell it all today you would earn a total of 0.00 from holding Blueprint Medicines Corporation or generate 0.0% return on investment in Blueprint Medicines over 30 days. Blueprint Medicines is related to or competes with NantKwest, Del Mar, Dimension Therapeutics, VBI Vaccines, Vascular Biogenics, and Vericel. Its lead drug candidates include BLU285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor ...

Blueprint Medicines Upside/Downside Indicators

  

Blueprint Medicines Market Premium Indicators

Blueprint Medicines lagged returns against current returns

 Current and Lagged Values 
      Timeline 

Blueprint Medicines regressed lagged prices vs. current prices

 Current vs Lagged Prices 
      Timeline 

Blueprint Medicines Backtested Returns

Macroaxis considers Blueprint Medicines not too volatile given 1 month investment horizon. Blueprint Medicines secures Sharpe Ratio (or Efficiency) of 0.1307 which signifies that Blueprint Medicines had 0.1307% of return per unit of risk over the last 1 month. Our philosophy towards foreseeing volatility of a stock is to use all available market data together with company specific technical indicators that cannot be diversified away. We have found twenty-eight technical indicators for Blueprint Medicines Corporation which you can use to evaluate future volatility of the firm. Please makes use of Blueprint Medicines Downside Deviation of 2.18, Risk Adjusted Performance of 0.0266 and Mean Deviation of 1.75 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100 Blueprint Medicines holds performance score of 8. The firm shows Beta (market volatility) of 1.1505 which signifies that as market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Blueprint Medicines will likely underperform.. Although it is vital to follow to Blueprint Medicines historical returns, it is good to be conservative about what you can actually do with the information regarding equity current trending patternss. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing Blueprint Medicines technical indicators you can presently evaluate if the expected return of 0.2884% will be sustainable into the future. Please makes use of Blueprint Medicines Expected Short fall, Day Median Price and the relationship between Potential Upside and Accumulation Distribution to make a quick decision on weather Blueprint Medicines price patterns will revert.
Advice Volatility Trend Exposure Correlations
15 days auto-correlation(0.59) 

Good reverse predictability

Blueprint Medicines Corporation has good reverse predictability. Overlapping area represents the amount of predictability between Blueprint Medicines time series from September 18, 2017 to October 3, 2017 and October 3, 2017 to October 18, 2017. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Blueprint Medicines price movement. The serial correlation of -0.59 indicates that roughly 59.0% of current Blueprint Medicines price fluctuation can be explain by its past prices. Given that Blueprint Medicines Corporation has negative autocorrelation for selected time horizon, investors may consider taking a contrarian position regarding future price movement of Blueprint Medicines for similar time interval.
Correlation Coefficient -0.59
Spearman Rank Test -0.43
Price Variance 3.38
Lagged Price Variance 9.7

Blueprint Medicines Lagged Returns

 Regressed Prices 
      Timeline 

Blueprint Medicines Performance vs DOW

The median price of Blueprint Medicines for the period between Mon, Sep 18, 2017 and Wed, Oct 18, 2017 is 66.05 with a coefficient of variation of 3.95. The daily time series for the period is distributed with a sample standard deviation of 2.58, arithmetic mean of 65.45, and mean deviation of 2.21. The Stock received some media coverage during the period.
Price Growth (%)  
      Timeline 
1
Sale by Haviland Kate of 700 shares of Blueprint Medicines10/13/2017